[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 40, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": 695178, "exercisedValue": 2794936, "unexercisedValue": 163438}, {"maxAge": 1, "name": "Ms. Tina Marriott Larson", "age": 48, "title": "COO & President", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 612689, "exercisedValue": 757472, "unexercisedValue": 4404300}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 41, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 39999, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Secora Ph.D.", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": 524188, "exercisedValue": 0, "unexercisedValue": 6742406}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "Vice President of Finance & Accounting", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 40, "title": "Chief Technology Officer", "yearBorn": 1983, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jared  Allenbach", "title": "Senior Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Hatfield", "title": "Chief Legal Officer & General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Kelly", "title": "Chief Communications Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Kinn", "title": "Chief Corporate Development Officer and SVP of Business Development & Corporate Initiatives", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.97, "open": 9.97, "dayLow": 9.33, "dayHigh": 9.97, "regularMarketPreviousClose": 9.97, "regularMarketOpen": 9.97, "regularMarketDayLow": 9.33, "regularMarketDayHigh": 9.97, "beta": 0.827, "forwardPE": -5.0376344, "volume": 6480911, "regularMarketVolume": 6480911, "averageVolume": 7226928, "averageVolume10days": 6463650, "averageDailyVolume10Day": 6463650, "marketCap": 2198698496, "fiftyTwoWeekLow": 4.54, "fiftyTwoWeekHigh": 16.745, "priceToSalesTrailing12Months": 49.32582, "fiftyDayAverage": 11.0955, "twoHundredDayAverage": 9.324125, "currency": "USD", "enterpriseValue": 2045530752, "floatShares": 187992469, "sharesOutstanding": 227143008, "sharesShort": 43520191, "sharesShortPriorMonth": 38240528, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.1855, "heldPercentInsiders": 0.057690002, "heldPercentInstitutions": 0.92406, "shortRatio": 4.45, "shortPercentOfFloat": 0.2785, "impliedSharesOutstanding": 234652992, "bookValue": 1.978, "priceToBook": 4.737108, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -328065984, "trailingEps": -1.58, "forwardEps": -1.86, "pegRatio": -0.48, "enterpriseToRevenue": 45.89, "enterpriseToEbitda": -6.281, "52WeekChange": 0.51750386, "SandP52WeekChange": 0.28136122, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RXRX", "underlyingSymbol": "RXRX", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1618579800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b61b6c65-adf4-3158-aa09-6b9439d85de8", "messageBoardId": "finmb_261401243", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.37, "targetHighPrice": 17.0, "targetLowPrice": 10.0, "targetMeanPrice": 13.0, "targetMedianPrice": 12.5, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 6, "totalCash": 391564992, "totalCashPerShare": 1.669, "ebitda": -325657984, "totalDebt": 50672000, "quickRatio": 4.236, "currentRatio": 4.703, "totalRevenue": 44575000, "debtToEquity": 10.934, "revenuePerShare": 0.214, "returnOnAssets": -0.32294, "returnOnEquity": -0.69122005, "freeCashflow": -187367120, "operatingCashflow": -287780000, "revenueGrowth": -0.204, "grossMargins": 0.0446, "operatingMargins": -9.19273, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]